{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:59:01Z","timestamp":1785153541724,"version":"3.55.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82572661"],"award-info":[{"award-number":["82572661"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discover Nano"],"DOI":"10.1186\/s11671-026-04819-9","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:27:54Z","timestamp":1785144474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease mechanisms and translational barriers guide nanocarrier design for nose to brain delivery in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Chenqi","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"10544","key":"4819_CR1","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/S0140-6736(26)00198-4","volume":"407","author":"A Serrano-Pozo","year":"2026","unstructured":"Serrano-Pozo A, Escott-Price V, Grinberg LT, Pascoal T, Suarez-Calvet M, Dubois B, et al. Alzheimer\u2019s disease. Lancet (London England). 2026;407(10544):2241\u201362.","journal-title":"Lancet"},{"issue":"2","key":"4819_CR2","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"Estimation of the global prevalence of dementia","year":"2022","unstructured":"Estimation of the global prevalence of dementia. in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public health. 2022;7(2):e105\u201325.","journal-title":"Lancet Public health"},{"key":"4819_CR3","doi-asserted-by":"crossref","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s & dementia: the journal of the Alzheimer\u2019s Association. 2024;20(5):3708\u2009\u2013\u2009821.","DOI":"10.1002\/alz.13809"},{"issue":"22","key":"4819_CR4","doi-asserted-by":"publisher","first-page":"13954","DOI":"10.3390\/ijms232213954","volume":"23","author":"E Passeri","year":"2022","unstructured":"Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Tamayol A, et al. Alzheimer\u2019s disease: treatment strategies and their limitations. Int J Mol Sci. 2022;23(22):13954.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4819_CR5","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00702-025-02956-6","volume":"132","author":"LB Chamorro","year":"2025","unstructured":"Chamorro LB, Zulli B, Barone E. Insulin resistance: fueling oxidative stress and neurodegeneration. J Neural Transm. 2025;132(10):1567\u201386.","journal-title":"J Neural Transm"},{"key":"4819_CR6","doi-asserted-by":"publisher","first-page":"102713","DOI":"10.1016\/j.arr.2025.102713","volume":"107","author":"MCB D\u2019Alessandro","year":"2025","unstructured":"D\u2019Alessandro MCB, Kanaan S, Geller M, Pratic\u00f2 D, Daher JPL. Mitochondrial dysfunction in Alzheimer\u2019s disease. Ageing Res Rev. 2025;107:102713.","journal-title":"Ageing Res Rev"},{"issue":"6","key":"4819_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3390\/pharmaceutics17060775","volume":"17","author":"X Wu","year":"2025","unstructured":"Wu X, Zang R, Qiu Y, Zhang Y, Peng J, Cheng Z, et al. Intranasal drug delivery technology in the treatment of central nervous system diseases: challenges, advances, and future research directions. Pharmaceutics. 2025;17(6):775.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4819_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13\u201325.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"4819_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40035-025-00481-w","volume":"14","author":"I Drath","year":"2025","unstructured":"Drath I, Richter F, Feja M. Nose-to-brain drug delivery: from bench to bedside. Translational neurodegeneration. 2025;14(1):23.","journal-title":"Translational neurodegeneration"},{"issue":"1","key":"4819_CR10","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/s41598-019-39191-5","volume":"9","author":"JJ Lochhead","year":"2019","unstructured":"Lochhead JJ, Kellohen KL, Ronaldson PT, Davis TP. Distribution of insulin in trigeminal nerve and brain after intranasal administration. Sci Rep. 2019;9(1):2621.","journal-title":"Sci Rep"},{"issue":"2","key":"4819_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","volume":"127","author":"RG Thorne","year":"2004","unstructured":"Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127(2):481\u201396.","journal-title":"Neuroscience"},{"key":"4819_CR12","doi-asserted-by":"publisher","first-page":"177958","DOI":"10.1016\/j.ejphar.2025.177958","volume":"1003","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Liu M, Wang Y, Hu D, Wu S, Zhao B, et al. Nasal nanotherapeutics for central nervous system disorders: Bridging the translational gap in central nervous system drug delivery. Eur J Pharmacol. 2025;1003:177958.","journal-title":"Eur J Pharmacol"},{"key":"4819_CR13","doi-asserted-by":"publisher","first-page":"979682","DOI":"10.3389\/fphar.2022.979682","volume":"13","author":"A Rajput","year":"2022","unstructured":"Rajput A, Pingale P, Dhapte-Pawar V. Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects. Front Pharmacol. 2022;13:979682.","journal-title":"Front Pharmacol"},{"key":"4819_CR14","doi-asserted-by":"publisher","first-page":"126011","DOI":"10.1016\/j.ijpharm.2025.126011","volume":"683","author":"VV Sugandhi","year":"2025","unstructured":"Sugandhi VV, Gattu K, Mundrathi V, Khairnar R, Arshad T, Kumar S, et al. Intranasal delivery of rapamycin via brain-targeting polymeric micelles for Alzheimer\u2019s disease treatment. Int J Pharm. 2025;683:126011.","journal-title":"Int J Pharm"},{"issue":"33","key":"4819_CR15","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.2174\/0929867330666221115103513","volume":"30","author":"L Zakharova","year":"2023","unstructured":"Zakharova L, Gaynanova G, Vasilieva E, Vasileva L, Pavlov R, Kashapov R, et al. Recent nanoscale carriers for therapy of Alzheimer\u2019s disease: current strategies and perspectives. Curr Med Chem. 2023;30(33):3743\u201374.","journal-title":"Curr Med Chem"},{"issue":"s1","key":"4819_CR16","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.3233\/JAD-240069","volume":"101","author":"SM de la Monte","year":"2024","unstructured":"de la Monte SM. Conquering insulin network dysfunctions in Alzheimer\u2019s disease: where are we today? J Alzheimer\u2019s disease: JAD. 2024;101(s1):S317\u201343.","journal-title":"J Alzheimer\u2019s disease: JAD"},{"issue":"10","key":"4819_CR17","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.neuron.2024.02.017","volume":"112","author":"D Zhang","year":"2024","unstructured":"Zhang D, Zhang W, Ming C, Gao X, Yuan H, Lin X, et al. P-tau217 correlates with neurodegeneration in Alzheimer\u2019s disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy. Neuron. 2024;112(10):1676\u2013e9312.","journal-title":"Neuron"},{"issue":"754","key":"4819_CR18","doi-asserted-by":"publisher","first-page":"eadj5958","DOI":"10.1126\/scitranslmed.adj5958","volume":"16","author":"S Gaikwad","year":"2024","unstructured":"Gaikwad S, Puangmalai N, Sonawane M, Montalbano M, Price R, Iyer MS, et al. Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice. Sci Transl Med. 2024;16(754):eadj5958.","journal-title":"Sci Transl Med"},{"issue":"1","key":"4819_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00401-025-02902-6","volume":"149","author":"M Dourte","year":"2025","unstructured":"Dourte M, Pa\u00eetre E, Bouchoucha M, Boyer E, Tom\u00e9 SO, Doeraene E, et al. The olfactory epithelium: a critical gateway for pathological tau propagation and a target for mitigating tauopathy in the central nervous system. Acta Neuropathol. 2025;149(1):64.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"4819_CR20","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1007\/s13346-024-01558-1","volume":"14","author":"CYJ Wong","year":"2024","unstructured":"Wong CYJ, Baldelli A, Hoyos CM, Tietz O, Ong HX, Traini D. Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer\u2019s disease therapy. Drug Del Translat Res. 2024;14(7):1776\u201393.","journal-title":"Drug delivery translational Res"},{"issue":"1","key":"4819_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40263-020-00781-x","volume":"35","author":"M Hallschmid","year":"2021","unstructured":"Hallschmid M. Intranasal insulin for Alzheimer\u2019s disease. CNS Drugs. 2021;35(1):21\u201337.","journal-title":"CNS Drugs"},{"issue":"11","key":"4819_CR22","doi-asserted-by":"publisher","first-page":"e12519","DOI":"10.1002\/jev2.12519","volume":"13","author":"LN Madhu","year":"2024","unstructured":"Madhu LN, Kodali M, Upadhya R, Rao S, Somayaji Y, Attaluri S, et al. Extracellular vesicles from human-induced pluripotent stem cell-derived neural stem cells alleviate proinflammatory cascades within disease-associated microglia in Alzheimer\u2019s disease. J Extracell vesicles. 2024;13(11):e12519.","journal-title":"J Extracell vesicles"},{"issue":"37","key":"4819_CR23","doi-asserted-by":"publisher","first-page":"e2309221120","DOI":"10.1073\/pnas.2309221120","volume":"120","author":"JR Lopes","year":"2023","unstructured":"Lopes JR, Zhang X, Mayrink J, Tatematsu BK, Guo L, LeServe DS, et al. Nasal administration of anti-CD3 monoclonal antibody ameliorates disease in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA. 2023;120(37):e2309221120.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"4819_CR24","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.3390\/ijms26136477","volume":"26","author":"M Kaluza","year":"2025","unstructured":"Kaluza M, Ksiazek-Winiarek D, Szpakowski P, Czpakowska J, Fijalkowska J, Glabinski A. Polyphenols in the central nervous system: cellular effects and liposomal delivery approaches. Int J Mol Sci. 2025;26(13):6477.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4819_CR25","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1007\/s10787-025-01854-3","volume":"33","author":"AM Mustafa","year":"2025","unstructured":"Mustafa AM, Bastawesy GA, Hatem S, Moussa RA, Hal DM, Fawzy MH, et al. Polyphenolic protection: the role of mangiferin in mitigating neurodegeneration and neuroinflammation. Inflammopharmacology. 2025;33(8):4535\u201352.","journal-title":"Inflammopharmacology"},{"key":"4819_CR26","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.2147\/IJN.S305851","volume":"16","author":"S Cunha","year":"2021","unstructured":"Cunha S, Forbes B, Sousa Lobo JM, Silva AC. Improving drug delivery for Alzheimer\u2019s disease through nose-to-brain delivery using nanoemulsions, nanostructured lipid carriers (NLC) and in situ hydrogels. Int J Nanomed. 2021;16:4373\u201390.","journal-title":"Int J Nanomed"},{"key":"4819_CR27","doi-asserted-by":"publisher","first-page":"115573","DOI":"10.1016\/j.addr.2025.115573","volume":"220","author":"A Galushkin","year":"2025","unstructured":"Galushkin A, Gozes I. Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity. Adv Drug Deliv Rev. 2025;220:115573.","journal-title":"Adv Drug Deliv Rev"},{"key":"4819_CR28","doi-asserted-by":"publisher","first-page":"177940","DOI":"10.1016\/j.ejphar.2025.177940","volume":"1003","author":"JL Bariviera","year":"2025","unstructured":"Bariviera JL, Ribeiro LR, Furian AF, Mello FK, Oliveira MS. Effects of intranasal antibodies on murine models of neurological disorders: a systematic review. Eur J Pharmacol. 2025;1003:177940.","journal-title":"Eur J Pharmacol"},{"issue":"46","key":"4819_CR29","doi-asserted-by":"publisher","first-page":"53177","DOI":"10.1021\/acsami.3c08756","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, Peng H, Zhang W, Li M, Wang N, Peng C, et al. Enhanced nose-to-brain delivery of combined small interfering rnas using lesion-recognizing nanoparticles for the synergistic therapy of Alzheimer\u2019s disease. ACS Appl Mater Interfaces. 2023;15(46):53177\u201388.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"8","key":"4819_CR30","doi-asserted-by":"publisher","first-page":"107321","DOI":"10.1016\/j.isci.2023.107321","volume":"26","author":"DD Wu","year":"2023","unstructured":"Wu DD, Salah YA, Ngowi EE, Zhang YX, Khattak S, Khan NH, et al. Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration. iScience. 2023;26(8):107321.","journal-title":"iScience"},{"key":"4819_CR31","doi-asserted-by":"publisher","first-page":"102088","DOI":"10.1016\/j.arr.2023.102088","volume":"92","author":"HA Rather","year":"2023","unstructured":"Rather HA, Almousa S, Craft S, Deep G. Therapeutic efficacy and promise of stem cell-derived extracellular vesicles in Alzheimer\u2019s disease and other aging-related disorders. Ageing Res Rev. 2023;92:102088.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"4819_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s13287-025-04555-4","volume":"16","author":"Z Hua","year":"2025","unstructured":"Hua Z, Zhou N, Zhou Z, Fu Z, Guo R, Akogo HY, et al. Intranasal administration of stem cell derivatives for the treatment of AD animal models: a systematic review and meta-analysis. Stem Cell Res Ther. 2025;16(1):409.","journal-title":"Stem Cell Res Ther"},{"key":"4819_CR33","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jconrel.2021.12.009","volume":"341","author":"H Goel","year":"2022","unstructured":"Goel H, Kalra V, Verma SK, Dubey SK, Tiwary AK. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies. J controlled release: official J Controlled Release Soc. 2022;341:782\u2013811.","journal-title":"J controlled release: official J Controlled Release Soc"},{"issue":"31","key":"4819_CR34","doi-asserted-by":"publisher","first-page":"17947","DOI":"10.1039\/D5NR00870K","volume":"17","author":"M Bolon","year":"2025","unstructured":"Bolon M, Fieux M, Monge C, Richard S. Polymeric nanoparticles for efficient nose-to-brain delivery. Nanoscale. 2025;17(31):17947\u201379.","journal-title":"Nanoscale"},{"issue":"3","key":"4819_CR35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/pharmaceutics15030829","volume":"15","author":"D Georgieva","year":"2023","unstructured":"Georgieva D, Nikolova D, Vassileva E, Kostova B. Chitosan-based nanoparticles for targeted nasal galantamine delivery as a promising tool in Alzheimer\u2019s disease therapy. Pharmaceutics. 2023;15(3):829.","journal-title":"Pharmaceutics"},{"key":"4819_CR36","doi-asserted-by":"publisher","first-page":"123809","DOI":"10.1016\/j.ijpharm.2024.123809","volume":"652","author":"H Guo","year":"2024","unstructured":"Guo H, Wang G, Zhai Z, Huang J, Huang Z, Zhou Y, et al. Rivastigmine nasal spray for the treatment of Alzheimer\u2019s disease: olfactory deposition and brain delivery. Int J Pharm. 2024;652:123809.","journal-title":"Int J Pharm"},{"key":"4819_CR37","first-page":"e70123","volume-title":"First-in-human positron emission tomography study of intranasal insulin in aging and MCI","author":"KKS Sai","year":"2025","unstructured":"Sai KKS, Erichsen JM, Gollapelli KK, Krizan I, Miller M, Damuka N, et al. First-in-human positron emission tomography study of intranasal insulin in aging and MCI. Volume 11. New York, N Y): Alzheimer\u2019s & dementia; 2025. p. e70123. 3."},{"issue":"1","key":"4819_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3233\/JAD-240484","volume":"101","author":"KK Solingapuram Sai","year":"2024","unstructured":"Solingapuram Sai KK, Erichsen JM, Gollapelli KK, Krizan I, Miller M, Bansode A, et al. First biodistribution study of [68Ga]Ga-NOTA-insulin following intranasal administration in adult vervet monkeys. J Alzheimer\u2019s disease: JAD. 2024;101(1):309\u201320.","journal-title":"J Alzheimer\u2019s disease: JAD"},{"key":"4819_CR39","doi-asserted-by":"crossref","unstructured":"Smith K, Fan J, Marriner GA, Gerdes J, Kessler R, Zinn KR. Distribution of insulin in primate brain following nose-to-brain transport. Volume 10. Alzheimer\u2019s & dementia; 2024. p. e12459. (New York, N Y). 1.","DOI":"10.1002\/trc2.12459"},{"key":"4819_CR40","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jconrel.2024.01.013","volume":"366","author":"S Ruan","year":"2024","unstructured":"Ruan S, Li J, Ruan H, Xia Q, Hou X, Wang Z, et al. Microneedle-mediated nose-to-brain drug delivery for improved Alzheimer\u2019s disease treatment. J Controlled Release Soc. 2024;366:712\u201331.","journal-title":"J controlled release: official J Controlled Release Soc"},{"issue":"8","key":"4819_CR41","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.xphs.2024.05.005","volume":"113","author":"D Mart\u00ednez-Ort\u00edz","year":"2024","unstructured":"Mart\u00ednez-Ort\u00edz D, Altshuler P, Mart\u00ednez-Ort\u00edz L, Rodr\u00edguez-de-Torner LA, Ch\u00e1vez-Linares O, Altshuler E. Nasal model experiments show that a collimated fluid delivers precise doses to the human olfactory cavity in the side-laying position. J Pharm Sci. 2024;113(8):2475\u201383.","journal-title":"J Pharm Sci"},{"key":"4819_CR42","doi-asserted-by":"publisher","first-page":"122038","DOI":"10.1016\/j.ijpharm.2022.122038","volume":"624","author":"M Perku\u0161i\u0107","year":"2022","unstructured":"Perku\u0161i\u0107 M, Ni\u017ei\u0107 Nodilo L, Ugrina I, \u0160poljari\u0107 D, Jakobu\u0161i\u0107 Brala C, Pepi\u0107 I, et al. Tailoring functional spray-dried powder platform for efficient donepezil nose-to-brain delivery. Int J Pharm. 2022;624:122038.","journal-title":"Int J Pharm"},{"issue":"6","key":"4819_CR43","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1021\/acsabm.5c00267","volume":"8","author":"JL Wang","year":"2025","unstructured":"Wang JL, Dong YY, Liu PL, Liao XR, Qi LJ, Huang QY, et al. Dual-Targeting Protein-Based Delivery System for enhanced drug therapy of neurodegenerative disorders. ACS Appl bio Mater. 2025;8(6):4898\u2013907.","journal-title":"ACS Appl bio Mater"},{"issue":"15","key":"4819_CR44","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1080\/09205063.2025.2492455","volume":"36","author":"RW Tuna","year":"2025","unstructured":"Tuna RW, Achmad NA, Kurniawan I, Khairiyah, Asaf MB, Sapiun Z, et al. Development of thermosensitive mucoadhesive gel incorporated lipid microspheres of donepezil for enhanced nose-to-brain delivery. J biomaterials Sci Polym Ed. 2025;36(15):2159\u201386.","journal-title":"J biomaterials Sci Polym Ed"},{"issue":"7","key":"4819_CR45","first-page":"1934","volume":"113","author":"HF Salem","year":"2024","unstructured":"Salem HF, Aboud HM, Abdellatif MM, Abou-Taleb HA. Nose-to-brain targeted delivery of donepezil hydrochloride via novel hyaluronic acid-doped nanotransfersomes for Alzheimer\u2019s disease mitigation. J Pharm Sci. 2024;113(7):1934\u201345.","journal-title":"J Pharm Sci"},{"issue":"9","key":"4819_CR46","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1021\/acs.molpharmaceut.3c00454","volume":"20","author":"M Handa","year":"2023","unstructured":"Handa M, Sanap SN, Bhatta RS, Patil GP, Palkhade R, Singh DP, et al. Simultaneous intranasal codelivery of donepezil and memantine in a nanocolloidal carrier: optimization, pharmacokinetics, and pharmacodynamics studies. Mol Pharm. 2023;20(9):4714\u201328.","journal-title":"Mol Pharm"},{"issue":"2","key":"4819_CR47","first-page":"101130","volume":"21","author":"G Wang","year":"2026","unstructured":"Wang G, Duan X, Ouyang D, Zhou J, Zhang H, Ding Y. Nose-to-brain delivery of donepezil within a small dose improves bioavailability and efficacy for Alzheimer\u2019s disease treatment. Asian J Pharm Sci. 2026;21(2):101130.","journal-title":"Asian J Pharm Sci"},{"issue":"1","key":"4819_CR48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/acs.molpharmaceut.5c00761","volume":"23","author":"T Suthar","year":"2026","unstructured":"Suthar T, Maurya R, Sonwani A, Upadhayay P, Datusalia AK, Naqvi S, et al. Nose-to-brain delivery of donepezil hydrochloride via Oleic acid-conjugated PAMAM G4 dendrimers for the treatment of Alzheimer\u2019s-like dementia. Mol Pharm. 2026;23(1):177\u201395.","journal-title":"Mol Pharm"},{"issue":"1","key":"4819_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s11671-025-04276-w","volume":"20","author":"SA Khan","year":"2025","unstructured":"Khan SA, Qamar Z, Kamboj S, Moonis M, Rai G, Dang S, et al. Nose to brain delivery of nanostructured lipid carriers loaded with rivastigmine and nilotinib for treating Alzheimer\u2019s disease: preparation, cell line study, and in vivo evaluation. Discover nano. 2025;20(1):93.","journal-title":"Discover nano"},{"key":"4819_CR50","doi-asserted-by":"publisher","first-page":"125635","DOI":"10.1016\/j.ijpharm.2025.125635","volume":"677","author":"V Kalra","year":"2025","unstructured":"Kalra V, Silakari O, Tiwary AK. Intranasal administration of in silico designed Rivastigmine mucoadhesive nanoparticles ameliorates scopolamine-induced Alzheimer\u2019s symptoms in mice: Pharmacokinetic and pharmacodynamic evidences. Int J Pharm. 2025;677:125635.","journal-title":"Int J Pharm"},{"key":"4819_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejpb.2023.06.007","volume":"190","author":"N Subhash Hinge","year":"2023","unstructured":"Subhash Hinge N, Kathuria H, Monohar Pandey M. Rivastigmine-DHA ion-pair complex improved loading in hybrid nanoparticles for better amyloid inhibition and nose-to-brain targeting in Alzheimer\u2019s. Eur J Pharm biopharmaceutics: official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2023;190:131\u201349.","journal-title":"Eur J Pharm biopharmaceutics: official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV"},{"issue":"Pt 1","key":"4819_CR52","doi-asserted-by":"publisher","first-page":"145647","DOI":"10.1016\/j.ijbiomac.2025.145647","volume":"320","author":"M Lotfi","year":"2025","unstructured":"Lotfi M, Nakhlband A, Doustmihan A, Omidi Y, Fathi M, Adibkia K. Formulation and evaluation of in-situ forming poloxamer-based hydrogel containing thiolated chitosan nanoparticles as intranasal galantamine delivery system. Int J Biol Macromol. 2025;320(Pt 1):145647.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"4819_CR53","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3390\/ijms26041710","volume":"26","author":"AH Sadiq","year":"2025","unstructured":"Sadiq AH, Alam MJ, Begum F, Hasan M, Kristof J, Mamun MA, et al. Enhancing galantamine distribution in rat brain using microplasma-assisted nose-to-brain drug delivery. Int J Mol Sci. 2025;26(4):1710.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4819_CR54","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1007\/s10787-024-01541-9","volume":"32","author":"DE ElMosbah","year":"2024","unstructured":"ElMosbah DE, Khattab MS, Ibrahim MA, El-Asssal MI, Miniawy H. Preclinical efficacy of oral and nasal rivastigmine-loaded chitosan nano-particles on AlCl(3)-induced Alzheimer\u2019s-like disease in rats. Inflammopharmacology. 2024;32(6):3943\u201352.","journal-title":"Inflammopharmacology"},{"issue":"15","key":"4819_CR55","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2217\/nnm-2021-0051","volume":"16","author":"SO El-Ganainy","year":"2021","unstructured":"El-Ganainy SO, Gowayed MA, Agami M, Mohamed P, Belal M, Farid RM, et al. Galantamine nanoparticles outperform oral galantamine in an Alzheimer\u2019s rat model: pharmacokinetics and pharmacodynamics. Nanomed (London England). 2021;16(15):1281\u201396.","journal-title":"Nanomed (London England)"},{"issue":"10","key":"4819_CR56","doi-asserted-by":"publisher","first-page":"13029","DOI":"10.1007\/s12035-025-05079-x","volume":"62","author":"V Kurtukova","year":"2025","unstructured":"Kurtukova V, Aktas S, Pupure J, Narbute K, Muceniece R, Pilipenko V. Low-dose intranasal metformin exerts neuroprotective effects in a rat model of sporadic Alzheimer\u2019s disease. Mol Neurobiol. 2025;62(10):13029\u201343.","journal-title":"Mol Neurobiol"},{"key":"4819_CR57","doi-asserted-by":"publisher","first-page":"120538","DOI":"10.1016\/j.lfs.2022.120538","volume":"299","author":"I Kazkayasi","year":"2022","unstructured":"Kazkayasi I, Telli G, Nemutlu E, Uma S. Intranasal metformin treatment ameliorates cognitive functions via insulin signaling pathway in ICV-STZ-induced mice model of Alzheimer\u2019s disease. Life Sci. 2022;299:120538.","journal-title":"Life Sci"},{"issue":"Pt 3","key":"4819_CR58","doi-asserted-by":"publisher","first-page":"116616","DOI":"10.1016\/j.bcp.2024.116616","volume":"230","author":"F Gouveia","year":"2024","unstructured":"Gouveia F, Carona A, Lacerda M, Bicker J, Camins A, Teresa Cruz M, et al. Unveiling the potential of intranasal delivery of renin-angiotensin system drugs: Insights on the pharmacokinetics of irbesartan. Biochem Pharmacol. 2024;230(Pt 3):116616.","journal-title":"Biochem Pharmacol"},{"key":"4819_CR59","doi-asserted-by":"crossref","unstructured":"Gouveia F, P\u00e9rez MC, Bicker J, Silva A, Santos AE, Pereira CF, et al. Protective effects of irbesartan against neurodegeneration in APP\/PS1 mice: Unraveling its triple anti-apoptotic, anti-inflammatory and anti-oxidant action. Volume 188. Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie; 2025. p. 118167.","DOI":"10.1016\/j.biopha.2025.118167"},{"key":"4819_CR60","doi-asserted-by":"publisher","first-page":"111471","DOI":"10.1016\/j.intimp.2023.111471","volume":"128","author":"F Gouveia","year":"2024","unstructured":"Gouveia F, Fonseca C, Silva A, Camins A, Teresa Cruz M, Ettcheto M, et al. Intranasal irbesartan reverts cognitive decline and activates the PI3K\/AKT pathway in an LPS-induced neuroinflammation mice model. Int Immunopharmacol. 2024;128:111471.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"4819_CR61","doi-asserted-by":"publisher","first-page":"104241","DOI":"10.1016\/j.xphs.2026.104241","volume":"115","author":"GA Moubarak","year":"2026","unstructured":"Moubarak GA, Salama AH, Ali AA, Galal AF, Fouad SA, Eid HM. Intranasal delivery of chitosan-coated bilosomes for repurposing Olmesartan in Alzheimer\u2019s disease therapy: Formulation, optimization, pharmacokinetic and pharmacodynamic evaluation. J Pharm Sci. 2026;115(5):104241.","journal-title":"J Pharm Sci"},{"issue":"3","key":"4819_CR62","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00213-025-06865-0","volume":"243","author":"S Balki","year":"2025","unstructured":"Balki S, Gautam AS, Balaji PG, Yadav AK, Singh RK. Montelukast attenuated memory decline, neuroinflammatory and neurodegenerative biomarkers in A\u03b2(1\u201342) exposed model of alzheimer\u2019s disease in mice. Psychopharmacology. 2025;243(3):601\u201321.","journal-title":"Psychopharmacology"},{"issue":"1","key":"4819_CR63","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s42003-025-07599-7","volume":"8","author":"AC Groo","year":"2025","unstructured":"Groo AC, Curel T, Malzert-Fr\u00e9on A, S\u00e9guy L, Bento O, Corvaisier S, et al. Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer\u2019s disease by administration through an intranasal route. Commun biology. 2025;8(1):155.","journal-title":"Commun biology"},{"key":"4819_CR64","doi-asserted-by":"publisher","first-page":"1368291","DOI":"10.3389\/fnagi.2024.1368291","volume":"16","author":"A Imtiaz","year":"2024","unstructured":"Imtiaz A, Shimonaka S, Uddin MN, Elahi M, Ishiguro K, Hasegawa M, et al. Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer\u2019s disease seed-dependent formation of tau aggregates. Front Aging Neurosci. 2024;16:1368291.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"4819_CR65","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1080\/10717544.2021.1937383","volume":"28","author":"MM Wen","year":"2021","unstructured":"Wen MM, Ismail NIK, Nasra MMA, El-Kamel AH. Repurposing ibuprofen-loaded microemulsion for the management of Alzheimer\u2019s disease: evidence of potential intranasal brain targeting. Drug Delivery. 2021;28(1):1188\u2013203.","journal-title":"Drug Delivery"},{"issue":"Pt 1","key":"4819_CR66","doi-asserted-by":"publisher","first-page":"130015","DOI":"10.1016\/j.ijbiomac.2024.130015","volume":"262","author":"MVG Botan","year":"2024","unstructured":"Botan MVG, da Silva JB, Bruschi ML. Development of nanostructured environmentally responsive system containing hydroxypropyl methylcellulose for nose-to-brain administration of meloxicam. Int J Biol Macromol. 2024;262(Pt 1):130015.","journal-title":"Int J Biol Macromol"},{"key":"4819_CR67","doi-asserted-by":"publisher","first-page":"120724","DOI":"10.1016\/j.ijpharm.2021.120724","volume":"604","author":"H Akel","year":"2021","unstructured":"Akel H, Ismail R, Katona G, Sabir F, Ambrus R, Cs\u00f3ka I. A comparison study of lipid and polymeric nanoparticles in the nasal delivery of meloxicam: formulation, characterization, and in vitro evaluation. Int J Pharm. 2021;604:120724.","journal-title":"Int J Pharm"},{"issue":"50","key":"4819_CR68","first-page":"e2405781","volume":"20","author":"Q Feng","year":"2024","unstructured":"Feng Q, Zhang X, Zhao X, Liu J, Wang Q, Yao Y, et al. Intranasal delivery of pure nanodrug loaded liposomes for Alzheimer\u2019s disease treatment by efficiently regulating microglial polarization. Small. 2024;20(50):e2405781.","journal-title":"Germany)"},{"issue":"Pt 1","key":"4819_CR69","doi-asserted-by":"publisher","first-page":"143300","DOI":"10.1016\/j.ijbiomac.2025.143300","volume":"311","author":"A Malaiya","year":"2025","unstructured":"Malaiya A, Kenwat R, Mamgain A, Nayak P, Parker A, Paliwal SR, et al. Intranasal resveratrol delivery to the brain with chitosan-decorated bovine serum albumin nanoparticles: advancing Alzheimer\u2019s management in old female rats through QbD-based optimization, in vitro evaluation, and in vivo exploration. Int J Biol Macromol. 2025;311(Pt 1):143300.","journal-title":"Int J Biol Macromol"},{"key":"4819_CR70","doi-asserted-by":"publisher","first-page":"102689","DOI":"10.1016\/j.nano.2023.102689","volume":"51","author":"B Fonseca-Santos","year":"2023","unstructured":"Fonseca-Santos B, Cazarin CA, da Silva PB, Dos Santos KP, da Rocha MCO, Bao SN, et al. Intranasal in situ gelling liquid crystal for delivery of resveratrol ameliorates memory and neuroinflammation in Alzheimer\u2019s disease. Nanomedicine: Nanatechnol biology Med. 2023;51:102689.","journal-title":"Nanomedicine: Nanatechnol biology Med"},{"issue":"10","key":"4819_CR71","doi-asserted-by":"publisher","first-page":"13182","DOI":"10.1007\/s12035-025-05137-4","volume":"62","author":"B Satpathy","year":"2025","unstructured":"Satpathy B, Rajwar TK, Mishra A, Saha I, Rai VK, Sahoo RK, et al. Intra-nasal delivery of Quercetin-Loaded Nanostructured Lipid Carriers (NLCs) in the management of Alzheimer\u2019s disease: formulation, in vitro and in vivo assessment. Mol Neurobiol. 2025;62(10):13182\u2013209.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"4819_CR72","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1208\/s12249-024-02736-7","volume":"25","author":"D Sonawane","year":"2024","unstructured":"Sonawane D, Pokharkar V. Quercetin-loaded nanostructured lipid carrier in situ gel for brain targeting through intranasal route: formulation, in vivo pharmacokinetic and pharmacodynamic studies. AAPS PharmSciTech. 2024;25(2):30.","journal-title":"AAPS PharmSciTech"},{"key":"4819_CR73","doi-asserted-by":"publisher","first-page":"1572771","DOI":"10.3389\/fphar.2025.1572771","volume":"16","author":"X Mi","year":"2025","unstructured":"Mi X, Ruan X, Lin R, Huang S, Cai P, Chen X, et al. Intranasal administration of Ganoderma lucidum-derived exosome-like nanovesicles ameliorates cognitive impairment by reducing inflammation in a mouse model of Alzheimer\u2019s disease. Front Pharmacol. 2025;16:1572771.","journal-title":"Front Pharmacol"},{"issue":"7","key":"4819_CR74","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1021\/acsabm.5c00482","volume":"8","author":"PK Sirvi","year":"2025","unstructured":"Sirvi PK, Balaji PG, Kumar A, Alam MI, Sharma A, Das N, et al. Lactoferrin-anchored carboxymethyl pullulan-MgO nanocomposites for targeted delivery of trans-ferulic acid: physicochemical characterization, in vitro and ex vivo studies. ACS Appl bio Mater. 2025;8(7):5757\u201374.","journal-title":"ACS Appl bio Mater"},{"key":"4819_CR75","doi-asserted-by":"publisher","first-page":"111838","DOI":"10.1016\/j.colsurfb.2021.111838","volume":"205","author":"S Saini","year":"2021","unstructured":"Saini S, Sharma T, Jain A, Kaur H, Katare OP, Singh B. Systematically designed chitosan-coated solid lipid nanoparticles of ferulic acid for effective management of Alzheimer\u2019s disease: a preclinical evidence. Colloids and surfaces B. Biointerfaces. 2021;205:111838.","journal-title":"Biointerfaces"},{"key":"4819_CR76","doi-asserted-by":"publisher","first-page":"125565","DOI":"10.1016\/j.ijpharm.2025.125565","volume":"675","author":"A Prabakaran","year":"2025","unstructured":"Prabakaran A, Rakshit D, Patel I, Susanna KJ, Mishra A, Radhakrishnanand P, et al. Enhanced cognitive function in mice through intranasal delivery of sinapic acid via chitosan-coated solid lipid nanoparticles. Int J Pharm. 2025;675:125565.","journal-title":"Int J Pharm"},{"issue":"Pt 2","key":"4819_CR77","doi-asserted-by":"publisher","first-page":"141136","DOI":"10.1016\/j.ijbiomac.2025.141136","volume":"305","author":"A Prabakaran","year":"2025","unstructured":"Prabakaran A, Rakshit D, Patel I, Susanna KJ, Mishra A, Radhakrishnanand P, et al. Chitosan-coated nanostructured lipid carriers for intranasal delivery of sinapic acid in Abeta(1)(-)(42) induced C57BL\/6 mice for Alzheimer\u2019s disease treatment. Int J Biol Macromol. 2025;305(Pt 2):141136.","journal-title":"Int J Biol Macromol"},{"key":"4819_CR78","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.2147\/IJN.S506793","volume":"20","author":"C Sun","year":"2025","unstructured":"Sun C, Sha S, Shan Y, Gao X, Li L, Xing C, et al. Intranasal delivery of BACE1 siRNA and berberine via engineered stem cell exosomes for the treatment of Alzheimer\u2019s disease. Int J Nanomed. 2025;20:5873\u201391.","journal-title":"Int J Nanomed"},{"issue":"2","key":"4819_CR79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/08982104.2024.2431908","volume":"35","author":"S Bahndare","year":"2025","unstructured":"Bahndare S, Mathure D, Ranpise H, Salunke M, Awasthi R. Surface-modified liposomal in-situ nasal gel enhances brain targeting of berberine hydrochloride for Alzheimer\u2019s therapy: optimization and in vivo studies. J Liposome Res. 2025;35(2):135\u201352.","journal-title":"J Liposome Res"},{"key":"4819_CR80","doi-asserted-by":"publisher","first-page":"138336","DOI":"10.1016\/j.ijbiomac.2024.138336","volume":"286","author":"S Chakraborty","year":"2025","unstructured":"Chakraborty S, Karmakar V, Chatterjee K, Chatterjee A, Dwivedi M, Gorain B. Chitosan nanoparticle-mediated nose-to-brain delivery of naringenin: attenuating memory decline in experimental animals via behavioural assessment and modulation of biochemical parameters. Int J Biol Macromol. 2025;286:138336.","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"4819_CR81","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3390\/pharmaceutics14051003","volume":"14","author":"H Abbas","year":"2022","unstructured":"Abbas H, Sayed NSE, Youssef N, Mousa PMEG, Fayez MR, AM. Novel luteolin-loaded chitosan decorated nanoparticles for brain-targeting delivery in a sporadic Alzheimer\u2019s disease mouse model: focus on antioxidant, anti-inflammatory, and amyloidogenic pathways. Pharmaceutics. 2022;14(5):1003.","journal-title":"Pharmaceutics"},{"issue":"3","key":"4819_CR82","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3390\/pharmaceutics14030576","volume":"14","author":"MA Elsheikh","year":"2022","unstructured":"Elsheikh MA, El-Feky YA, Al-Sawahli MM, Ali ME, Fayez AM, Abbas H. A Brain-targeted approach to ameliorate memory disorders in a sporadic Alzheimer\u2019s disease mouse model via intranasal luteolin-loaded nanobilosomes. Pharmaceutics. 2022;14(3):576.","journal-title":"Pharmaceutics"},{"key":"4819_CR83","doi-asserted-by":"publisher","first-page":"1224856","DOI":"10.3389\/fphar.2023.1224856","volume":"14","author":"F Wu","year":"2023","unstructured":"Wu F, Huang M, Zuo X, Xie R, Liu J, Ke J, et al. Osthole\/borneol thermosensitive gel via intranasal administration enhances intracerebral bioavailability to improve cognitive impairment in APP\/PS1 transgenic mice. Front Pharmacol. 2023;14:1224856.","journal-title":"Front Pharmacol"},{"issue":"15","key":"4819_CR84","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/09205063.2022.2088527","volume":"33","author":"N Vasdev","year":"2022","unstructured":"Vasdev N, Handa M, Kesharwani P, Shukla R. Rosemary oil low energy nanoemulsion: optimization, microrheology, in silico, in vitro, and ex vivo characterization. J biomaterials Sci Polym Ed. 2022;33(15):1901\u201323.","journal-title":"J biomaterials Sci Polym Ed"},{"key":"4819_CR85","doi-asserted-by":"publisher","first-page":"963933","DOI":"10.3389\/fnagi.2022.963933","volume":"14","author":"C Long","year":"2022","unstructured":"Long C, Han X, Yang Y, Li T, Zhou Q, Chen Q. Efficacy of intranasal insulin in improving cognition in mild cognitive impairment or dementia: a systematic review and meta-analysis. Front Aging Neurosci. 2022;14:963933.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"4819_CR86","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41598-022-05165-3","volume":"12","author":"D Kellar","year":"2022","unstructured":"Kellar D, Register T, Lockhart SN, Aisen P, Raman R, Rissman RA, et al. Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer\u2019s disease: a randomized trial. Sci Rep. 2022;12(1):1346.","journal-title":"Sci Rep"},{"key":"4819_CR87","doi-asserted-by":"publisher","first-page":"123094","DOI":"10.1016\/j.lfs.2024.123094","volume":"357","author":"F Karimani","year":"2024","unstructured":"Karimani F, Asgari Taei A, Kaveh N, Rabiei Ghahfarokhi M, Abolghasemi Dehaqani MR, Dargahi L. Hippocampal sharp-wave ripples and hippocampal-prefrontal synchrony regulate memory-enhancing effects of intranasal insulin in an STZ-induced Alzheimer\u2019s model. Life Sci. 2024;357:123094.","journal-title":"Life Sci"},{"issue":"24","key":"4819_CR88","doi-asserted-by":"publisher","first-page":"15811","DOI":"10.3390\/ijms232415811","volume":"23","author":"A Woodfield","year":"2022","unstructured":"Woodfield A, Gonzales T, Helmerhorst E, Laws S, Newsholme P, Porter T, et al. Current insights on the use of insulin and the potential use of insulin mimetics in targeting insulin signalling in Alzheimer\u2019s disease. Int J Mol Sci. 2022;23(24):15811.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4819_CR89","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40266-021-00845-7","volume":"38","author":"M Rosenbloom","year":"2021","unstructured":"Rosenbloom M, Barclay TR, Kashyap B, Hage L, O\u2019Keefe LR, Svitak A, et al. A phase II, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer\u2019s disease. Drugs Aging. 2021;38(5):407\u201315.","journal-title":"Drugs Aging"},{"issue":"1","key":"4819_CR90","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12987-023-00431-6","volume":"20","author":"V Nguyen","year":"2023","unstructured":"Nguyen V, Thomas P, Pemberton S, Babin A, Noonan C, Weaver R, et al. Central nervous system insulin signaling can influence the rate of insulin influx into brain. Fluids Barr CNS. 2023;20(1):28.","journal-title":"Fluids barriers CNS"},{"key":"4819_CR91","doi-asserted-by":"crossref","unstructured":"Khan TTS, Wong CYJ, Sheikh Z, Fathi A, Maleknia S, Oveissi F et al. Repurposing insulin for Alzheimer\u2019s disease treatment: intranasal delivery of a thermoresponsive nanocarrier-based insulin formulation to the brain. Drug delivery and translational research. 2026.","DOI":"10.1007\/s13346-026-02146-1"},{"issue":"1","key":"4819_CR92","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13195-024-01537-1","volume":"16","author":"N Abdulhameed","year":"2024","unstructured":"Abdulhameed N, Babin A, Hansen K, Weaver R, Banks WA, Talbot K, et al. Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP\/PS1 mouse model of Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):173.","journal-title":"Alzheimers Res Ther"},{"key":"4819_CR93","doi-asserted-by":"publisher","first-page":"101979","DOI":"10.1016\/j.arr.2023.101979","volume":"89","author":"J Nowell","year":"2023","unstructured":"Nowell J, Blunt E, Gupta D, Edison P. Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease. Ageing Res Rev. 2023;89:101979.","journal-title":"Ageing Res Rev"},{"issue":"2","key":"4819_CR94","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/jpet.107.129551","volume":"323","author":"I Vulih-Shultzman","year":"2007","unstructured":"Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther. 2007;323(2):438\u201349.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4819_CR95","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41398-024-03118-0","volume":"14","author":"I Gozes","year":"2024","unstructured":"Gozes I, Blatt J, Lobyntseva A. Davunetide sex-dependently boosts memory in prodromal Alzheimer\u2019s disease. Translation Psych. 2024;14(1):412.","journal-title":"Translational psychiatry"},{"key":"4819_CR96","doi-asserted-by":"publisher","first-page":"114661","DOI":"10.1016\/j.ejpb.2025.114661","volume":"208","author":"Y Hatakawa","year":"2025","unstructured":"Hatakawa Y, Tanaka A, Furubayashi T, Katsumi H, Nakamura R, Konishi M, et al. Efficient nose-to-brain delivery of nine residues peptide (JAL-TA9) exhibiting hydrolytic activity against amyloid-beta. Eur J Pharm biopharmaceutics: official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2025;208:114661.","journal-title":"Eur J Pharm biopharmaceutics: official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV"},{"issue":"10","key":"4819_CR97","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/pharmaceutics13101673","volume":"13","author":"Y Hatakawa","year":"2021","unstructured":"Hatakawa Y, Tanaka A, Furubayashi T, Nakamura R, Konishi M, Akizawa T, et al. Direct delivery of ANA-TA9, a peptide capable of Abeta hydrolysis, to the brain by intranasal administration. Pharmaceutics. 2021;13(10):1673.","journal-title":"Pharmaceutics"},{"issue":"3","key":"4819_CR98","doi-asserted-by":"publisher","first-page":"e70024","DOI":"10.1002\/alz.70024","volume":"21","author":"X Li","year":"2025","unstructured":"Li X, Liu C, Li W, Qi G, Dai Y, Gu C, et al. Multi-omics delineate growth factor network underlying exercise effects in an Alzheimer\u2019s mouse model. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2025;21(3):e70024.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"9","key":"4819_CR99","doi-asserted-by":"publisher","first-page":"e13937","DOI":"10.1111\/acel.13937","volume":"22","author":"K Guo","year":"2023","unstructured":"Guo K, Huang W, Chen K, Huang P, Peng W, Shi R, et al. Fibroblast growth factor 10 ameliorates neurodegeneration in mouse and cellular models of Alzheimer\u2019s disease via reducing tau hyperphosphorylation and neuronal apoptosis. Aging Cell. 2023;22(9):e13937.","journal-title":"Aging Cell"},{"issue":"6","key":"4819_CR100","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/cns.14160","volume":"29","author":"GS Fitzgerald","year":"2023","unstructured":"Fitzgerald GS, Chuchta TG, McNay EC. Insulin-like growth factor-2 is a promising candidate for the treatment and prevention of Alzheimer\u2019s disease. CNS Neurosci Ther. 2023;29(6):1449\u201369.","journal-title":"CNS Neurosci Ther"},{"issue":"6","key":"4819_CR101","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1021\/acs.molpharmaceut.3c00031","volume":"20","author":"A Gothwal","year":"2023","unstructured":"Gothwal A, Lamptey RNL, Singh J. Multifunctionalized cationic chitosan polymeric micelles polyplexed with pVGF for noninvasive delivery to the mouse brain through the intranasal route for developing therapeutics for Alzheimer\u2019s disease. Mol Pharm. 2023;20(6):3009\u201319.","journal-title":"Mol Pharm"},{"key":"4819_CR102","doi-asserted-by":"publisher","first-page":"754502","DOI":"10.3389\/fphar.2021.754502","volume":"12","author":"L Manni","year":"2021","unstructured":"Manni L, Conti G, Chiaretti A, Soligo M. Intranasal Delivery of nerve growth factor in neurodegenerative diseases and neurotrauma. Front Pharmacol. 2021;12:754502.","journal-title":"Front Pharmacol"},{"issue":"9","key":"4819_CR103","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.4103\/1673-5374.306062","volume":"16","author":"G Eftimiadi","year":"2021","unstructured":"Eftimiadi G, Soligo M, Manni L, Di Giuda D, Calcagni ML, Chiaretti A. Topical delivery of nerve growth factor for treatment of ocular and brain disorders. Neural regeneration Res. 2021;16(9):1740\u201350.","journal-title":"Neural regeneration Res"},{"issue":"12","key":"4819_CR104","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3390\/cells9122651","volume":"9","author":"C Petrella","year":"2020","unstructured":"Petrella C, Ciotti MT, Nistic\u00f2 R, Piccinin S, Calissano P, Capsoni S, et al. Involvement of bradykinin receptor 2 in nerve growth factor neuroprotective activity. Cells. 2020;9(12):2651.","journal-title":"Cells"},{"issue":"10","key":"4819_CR105","doi-asserted-by":"publisher","first-page":"13616","DOI":"10.1007\/s12035-025-05135-6","volume":"62","author":"NV Bobkova","year":"2025","unstructured":"Bobkova NV, Chuvakova LN, Kononova SV, Kovalev VI, Sukhikh GT, Zatsepina OG, et al. Similar normalizing effect of HSP70 and YB-1 stress proteins on the brain transcription of a mouse model of Alzheimer\u2019s disease. Mol Neurobiol. 2025;62(10):13616\u201335.","journal-title":"Mol Neurobiol"},{"issue":"11","key":"4819_CR106","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.7150\/thno.98587","volume":"14","author":"C Ye","year":"2024","unstructured":"Ye C, Wang S, Niu L, Yang F, Wang G, Wang S, et al. Unlocking potential of oxytocin: improving intracranial lymphatic drainage for Alzheimer\u2019s disease treatment. Theranostics. 2024;14(11):4331\u201351.","journal-title":"Theranostics"},{"issue":"4","key":"4819_CR107","doi-asserted-by":"publisher","first-page":"106545","DOI":"10.1016\/j.isci.2023.106545","volume":"26","author":"MC Selles","year":"2023","unstructured":"Selles MC, Fortuna JTS, de Faria YPR, Siqueira LD, Lima-Filho R, Longo BM, et al. Oxytocin attenuates microglial activation and restores social and non-social memory in APP\/PS1 Alzheimer model mice. iScience. 2023;26(4):106545.","journal-title":"iScience"},{"issue":"1","key":"4819_CR108","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s40001-024-01987-1","volume":"29","author":"R Rahimi Darehbagh","year":"2024","unstructured":"Rahimi Darehbagh R, Seyedoshohadaei SA, Ramezani R, Rezaei N. Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. Eur J Med Res. 2024;29(1):386.","journal-title":"Eur J Med Res"},{"key":"4819_CR109","doi-asserted-by":"publisher","first-page":"1200445","DOI":"10.3389\/fnagi.2023.1200445","volume":"15","author":"S Attaluri","year":"2023","unstructured":"Attaluri S, Jaimes Gonzalez J, Kirmani M, Vogel AD, Upadhya R, Kodali M, et al. Intranasally administered extracellular vesicles from human induced pluripotent stem cell-derived neural stem cells quickly incorporate into neurons and microglia in 5xFAD mice. Front Aging Neurosci. 2023;15:1200445.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"4819_CR110","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1007\/s12035-023-03733-w","volume":"61","author":"M Pourhadi","year":"2024","unstructured":"Pourhadi M, Zali H, Ghasemi R, Faizi M, Mojab F, Soufi Zomorrod M. Restoring Synaptic Function: How intranasal delivery of 3D-cultured hUSSC exosomes improve learning and memory deficits in Alzheimer\u2019s disease. Mol Neurobiol. 2024;61(6):3724\u201341.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"4819_CR111","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40035-023-00384-8","volume":"12","author":"H Mo","year":"2023","unstructured":"Mo H, Kim J, Kim JY, Kim JW, Han H, Choi SH, et al. Intranasal administration of induced pluripotent stem cell-derived cortical neural stem cell-secretome as a treatment option for Alzheimer\u2019s disease. Translational neurodegeneration. 2023;12(1):50.","journal-title":"Translational neurodegeneration"},{"issue":"5","key":"4819_CR112","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/biomedicines10050985","volume":"10","author":"T Di Musumeci","year":"2022","unstructured":"Musumeci T, Di Benedetto G, Carbone C, Bonaccorso A, Amato G, Lo Faro MJ, et al. Intranasal administration of a TRAIL neutralizing monoclonal antibody adsorbed in PLGA nanoparticles and NLC nanosystems: an in vivo study on a mouse model of Alzheimer\u2019s disease. Biomedicines. 2022;10(5):985.","journal-title":"Biomedicines"},{"issue":"8","key":"4819_CR113","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/RLU.0000000000005955","volume":"50","author":"T Singhal","year":"2025","unstructured":"Singhal T, Cicero S, Gale SA, Horan N, Dubey S, Marshall GA, et al. Dampening of microglial activation with nasal foralumab administration in moderate Alzheimer\u2019s disease dementia. Clin Nucl Med. 2025;50(8):756\u20137.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"4819_CR114","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s13346-022-01117-6","volume":"12","author":"N Kamei","year":"2022","unstructured":"Kamei N, Hashimoto A, Tanaka E, Murata K, Yamaguchi M, Yokoyama N, et al. Therapeutic effects of anti-amyloid beta antibody after intravenous injection and efficient nose-to-brain delivery in Alzheimer\u2019s disease mouse model. Drug delivery translational Res. 2022;12(11):2667\u201377.","journal-title":"Drug delivery translational Res"},{"issue":"5","key":"4819_CR115","doi-asserted-by":"publisher","first-page":"e101143","DOI":"10.1136\/gpsych-2023-101143","volume":"36","author":"X Xie","year":"2023","unstructured":"Xie X, Song Q, Dai C, Cui S, Tang R, Li S, et al. Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer\u2019s disease: a phase I\/II clinical trial. Gen psychiatry. 2023;36(5):e101143.","journal-title":"Gen psychiatry"},{"issue":"6","key":"4819_CR116","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1016\/j.apsb.2025.02.035","volume":"15","author":"Y Xu","year":"2025","unstructured":"Xu Y, Ye X, Du Y, Yang W, Tong F, Li W, et al. Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged beta-amyloid nanoscavenger for Alzheimer\u2019s disease therapy. Acta Pharm Sinica B. 2025;15(6):2884\u201399.","journal-title":"Acta Pharm Sinica B"},{"issue":"30","key":"4819_CR117","doi-asserted-by":"publisher","first-page":"e2203182","DOI":"10.1002\/smll.202203182","volume":"18","author":"X Yang","year":"2022","unstructured":"Yang X, Yang W, Xia X, Lei T, Yang Z, Jia W, et al. Intranasal delivery of BACE1 siRNA and rapamycin by dual targets modified nanoparticles for Alzheimer\u2019s disease therapy. Small. 2022;18(30):e2203182.","journal-title":"Small"},{"issue":"19","key":"4819_CR118","doi-asserted-by":"publisher","first-page":"7623","DOI":"10.7150\/thno.103596","volume":"14","author":"D Peng","year":"2024","unstructured":"Peng D, Liu T, Lu H, Zhang L, Chen H, Huang Y, et al. Intranasal delivery of engineered extracellular vesicles loaded with miR-206-3p antagomir ameliorates Alzheimer\u2019s disease phenotypes. Theranostics. 2024;14(19):7623\u201344.","journal-title":"Theranostics"},{"issue":"2","key":"4819_CR119","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.apsb.2023.10.015","volume":"14","author":"M Luo","year":"2024","unstructured":"Luo M, Pang Y, Li J, Yi L, Wu B, Tian Q, et al. miR-429-3p mediates memory decline by targeting MKP-1 to reduce surface GluA1-containing AMPA receptors in a mouse model of Alzheimer\u2019s disease. Acta Pharm Sinica B. 2024;14(2):635\u201352.","journal-title":"Acta Pharm Sinica B"},{"issue":"6","key":"4819_CR120","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1021\/acsbiomaterials.5c00465","volume":"11","author":"AK Mahanta","year":"2025","unstructured":"Mahanta AK, Chaulagain B, Gothwal A, Singh J. Engineered PLGA nanoparticles for brain-targeted codelivery of cannabidiol and pApoE2 through the intranasal route for the treatment of Alzheimer\u2019s disease. ACS biomaterials Sci Eng. 2025;11(6):3533\u201346.","journal-title":"ACS biomaterials Sci Eng"},{"issue":"Pt 4","key":"4819_CR121","doi-asserted-by":"publisher","first-page":"143542","DOI":"10.1016\/j.ijbiomac.2025.143542","volume":"310","author":"A Gothwal","year":"2025","unstructured":"Gothwal A, Muolokwu CE, Chaulagain B, Mahanta AK, Singh J. Intranasal delivery of pApoE2 via penetratin-mannose multi-functionalized chitosan polymeric micelles to the brain: Reduced total tau and phosphorylated tau burden in transgenic Alzheimer\u2019s mouse model. Int J Biol Macromol. 2025;310(Pt 4):143542.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"4819_CR122","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41368-022-00199-9","volume":"14","author":"Y Lin","year":"2022","unstructured":"Lin Y, Li Q, Wang L, Guo Q, Liu S, Zhu S, et al. Advances in regenerative medicine applications of tetrahedral framework nucleic acid-based nanomaterials: an expert consensus recommendation. Int J Oral Sci. 2022;14(1):51.","journal-title":"Int J Oral Sci"},{"issue":"1","key":"4819_CR123","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s12951-024-02963-x","volume":"22","author":"L Tan","year":"2024","unstructured":"Tan L, Xie J, Liao C, Li X, Zhang W, Cai C, et al. Tetrahedral framework nucleic acids inhibit Abeta-mediated ferroptosis and ameliorate cognitive and synaptic impairments in Alzheimer\u2019s disease. J Nanobiotechnol. 2024;22(1):682.","journal-title":"J Nanobiotechnol"},{"issue":"33","key":"4819_CR124","doi-asserted-by":"publisher","first-page":"35223","DOI":"10.1021\/acsomega.4c01774","volume":"9","author":"O Ozceylan","year":"2024","unstructured":"Ozceylan O, Sezgin-Bayindir Z. Current overview on the use of nanosized drug delivery systems in the treatment of neurodegenerative diseases. ACS Omega. 2024;9(33):35223\u201342.","journal-title":"ACS omega"},{"issue":"3","key":"4819_CR125","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s11064-021-03488-7","volume":"47","author":"TT Nguyen","year":"2022","unstructured":"Nguyen TT, Nguyen TTD, Tran NM, Van Vo G. Lipid-based nanocarriers via nose-to-brain pathway for central nervous system disorders. Neurochem Res. 2022;47(3):552\u201373.","journal-title":"Neurochem Res"},{"key":"4819_CR126","doi-asserted-by":"publisher","first-page":"12343","DOI":"10.2147\/IJN.S497480","volume":"19","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Cui L, Lu H, Liu Z, Zhai Z, Wang H, et al. Nose to brain: exploring the progress of intranasal delivery of solid lipid nanoparticles and nanostructured lipid carriers. Int J Nanomed. 2024;19:12343\u201368.","journal-title":"Int J Nanomed"},{"issue":"13","key":"4819_CR127","doi-asserted-by":"publisher","first-page":"10494","DOI":"10.3390\/ijms241310494","volume":"24","author":"L Vasileva","year":"2023","unstructured":"Vasileva L, Gaynanova G, Valeeva F, Belyaev G, Zueva I, Bushmeleva K, et al. Mitochondria-targeted delivery strategy of dual-loaded liposomes for alzheimer\u2019s disease therapy. Int J Mol Sci. 2023;24(13):10494.","journal-title":"Int J Mol Sci"},{"key":"4819_CR128","doi-asserted-by":"publisher","first-page":"732954","DOI":"10.3389\/fphar.2021.732954","volume":"12","author":"LM Spindler","year":"2021","unstructured":"Spindler LM, Feuerhake A, Ladel S, G\u00fcnday C, Flamm J, G\u00fcnday-T\u00fcreli N, et al. Nano-in-micro-particles consisting of PLGA nanoparticles embedded in chitosan microparticles via spray-drying enhances their uptake in the Olfactory Mucosa. Front Pharmacol. 2021;12:732954.","journal-title":"Front Pharmacol"},{"key":"4819_CR129","doi-asserted-by":"publisher","first-page":"124814","DOI":"10.1016\/j.ijpharm.2024.124814","volume":"666","author":"BA Abou-Taleb","year":"2024","unstructured":"Abou-Taleb BA, El-Hadidy WF, Masoud IM, Matar NA, Hussein HS. Dihydroquercetin nanoparticles nasal gel is a promising formulation for amelioration of Alzheimer\u2019s disease. Int J Pharm. 2024;666:124814.","journal-title":"Int J Pharm"},{"issue":"1","key":"4819_CR130","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/02652048.2023.2282968","volume":"41","author":"G Camlik","year":"2024","unstructured":"Camlik G, Bilakaya B, Ozsoy Y, Degim IT. A new approach for the treatment of Alzheimer\u2019s disease: insulin-quantum dots. J Microencapsul. 2024;41(1):18\u201326.","journal-title":"J Microencapsul"},{"issue":"40","key":"4819_CR131","doi-asserted-by":"publisher","first-page":"e2207626","DOI":"10.1002\/smll.202207626","volume":"19","author":"F Mohebichamkhorami","year":"2023","unstructured":"Mohebichamkhorami F, Faizi M, Mahmoudifard M, Hajikarim-Hamedani A, Mohseni SS, Heidari A, et al. Microfluidic synthesis of ultrasmall chitosan\/graphene quantum dots particles for intranasal delivery in Alzheimer\u2019s disease treatment. Small. 2023;19(40):e2207626.","journal-title":"Small"},{"key":"4819_CR132","doi-asserted-by":"publisher","first-page":"114667","DOI":"10.1016\/j.jconrel.2026.114667","volume":"392","author":"Z Zhai","year":"2026","unstructured":"Zhai Z, Wang W, Wang G, Wei C, Wei S, Li J, et al. Rationalizing nose-to-brain drug delivery: Machine learning-guided optimization and mechanistic elucidation of olfactory deposition for nasal sprays. J Controlled Release Soc. 2026;392:114667.","journal-title":"J controlled release: official J Controlled Release Soc"},{"key":"4819_CR133","doi-asserted-by":"publisher","first-page":"122588","DOI":"10.1016\/j.ijpharm.2023.122588","volume":"632","author":"M Elhabak","year":"2023","unstructured":"Elhabak M, Salama AAA, Salama AH. Nose-to-brain delivery of galantamine loaded nanospray dried polyacrylic acid\/taurodeoxycholate mixed matrix as a protective therapy in lipopolysaccharide-induced Alzheimer\u2019s in mice model. Int J Pharm. 2023;632:122588.","journal-title":"Int J Pharm"},{"issue":"5","key":"4819_CR134","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/molecules30051169","volume":"30","author":"N Zoupanou","year":"2025","unstructured":"Zoupanou N, Papakyriakopoulou P, Georgiou N, Cheilari A, Javornik U, Podbevsek P, et al. Spectroscopic characterization using (1)H and (13)C nuclear magnetic resonance and computational analysis of the complex of donepezil with 2,6-methyl-beta-cyclodextrin and hydroxy propyl methyl cellulose. Molecules. 2025;30(5):1169.","journal-title":"Molecules"},{"issue":"Pt 6","key":"4819_CR135","doi-asserted-by":"publisher","first-page":"127217","DOI":"10.1016\/j.ijbiomac.2023.127217","volume":"253","author":"S Hard","year":"2023","unstructured":"Hard S, Shivakumar HN, Redhwan MAM. Development and optimization of in-situ gel containing chitosan nanoparticles for possible nose-to-brain delivery of vinpocetine. Int J Biol Macromol. 2023;253(Pt 6):127217.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"4819_CR136","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/1061186X.2024.2433557","volume":"33","author":"S Hard","year":"2025","unstructured":"Hard S, Shivakumar HN, Bafail DA, Moqbel Redhwan MA. Development of in vitro and in vivo evaluation of mucoadhesive in-situ gel for intranasal delivery of vinpocetine. J Drug Target. 2025;33(4):528\u201345.","journal-title":"J Drug Target"},{"issue":"1","key":"4819_CR137","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1021\/acs.langmuir.4c03530","volume":"41","author":"NA Achmad","year":"2025","unstructured":"Achmad NA, Tuna RW, Kurniawan I, Khairiyah, Asaf MB, Rahman L, et al. Development of thermosensitive mucoadhesive gel based encapsulated lipid microspheres as nose-to-brain rivastigmine delivery system. Langmuir. 2025;41(1):314\u201328.","journal-title":"Langmuir"},{"issue":"15","key":"4819_CR138","doi-asserted-by":"publisher","first-page":"7467","DOI":"10.7150\/thno.112213","volume":"15","author":"J Xie","year":"2025","unstructured":"Xie J, Cao K, Liu L, Zhang L, Yang Y, Gong H, et al. Mn(3)O(4) nanozyme-based anti-inflammatory therapy modulates microglial phenotype by downregulating TLR4\/NOX2 expression and further alleviates Alzheimer\u2019s disease pathology. Theranostics. 2025;15(15):7467\u201388.","journal-title":"Theranostics"},{"issue":"49","key":"4819_CR139","doi-asserted-by":"publisher","first-page":"e2402604121","DOI":"10.1073\/pnas.2402604121","volume":"121","author":"F Natale","year":"2024","unstructured":"Natale F, Spinelli M, Rinaudo M, Gulisano W, Nifo Sarrapochiello I, Aceto G, et al. Inhibition of zDHHC7-driven protein S-palmitoylation prevents cognitive deficits in an experimental model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA. 2024;121(49):e2402604121.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"4819_CR140","doi-asserted-by":"publisher","first-page":"e176703","DOI":"10.1172\/jci.insight.176703","volume":"9","author":"C Liu","year":"2024","unstructured":"Liu C, Meng L, Gao Y, Chen J, Zhu M, Xiong M, et al. PM2.5 triggers tau aggregation in a mouse model of tauopathy. JCI Insight. 2024;9(14):e176703.","journal-title":"JCI Insight"},{"issue":"2","key":"4819_CR141","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s43440-024-00692-4","volume":"77","author":"RK Singh","year":"2025","unstructured":"Singh RK. Intranasal amyloid model of Alzheimer\u2019s disease - potential opportunities and challenges. Pharmacol Rep. 2025;77(2):425\u201333.","journal-title":"Pharmacol Rep"},{"issue":"3","key":"4819_CR142","doi-asserted-by":"publisher","first-page":"240","DOI":"10.14283\/jpad.2021.14","volume":"8","author":"D Kellar","year":"2021","unstructured":"Kellar D, Lockhart SN, Aisen P, Raman R, Rissman RA, Brewer J, et al. Intranasal insulin reduces white matter hyperintensity progression in association with improvements in cognition and CSF biomarker profiles in mild cognitive impairment and Alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis. 2021;8(3):240\u20138.","journal-title":"J Prev Alzheimer\u2019s disease"},{"issue":"9","key":"4819_CR143","doi-asserted-by":"publisher","first-page":"afae188","DOI":"10.1093\/ageing\/afae188","volume":"53","author":"M Sun","year":"2024","unstructured":"Sun M, Ruan X, Zhou Z, Huo Y, Liu M, Liu S, et al. Effect of intranasal insulin on perioperative cognitive function in older adults: a randomized, placebo-controlled, double-blind clinical trial. Age Ageing. 2024;53(9):afae188.","journal-title":"Age Ageing"},{"issue":"9","key":"4819_CR144","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","volume":"77","author":"S Craft","year":"2020","unstructured":"Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77(9):1099\u2013109.","journal-title":"JAMA Neurol"}],"container-title":["Discover Nano"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04819-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11671-026-04819-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04819-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:02:24Z","timestamp":1785150144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11671-026-04819-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4819"],"URL":"https:\/\/doi.org\/10.1186\/s11671-026-04819-9","relation":{},"ISSN":["2731-9229"],"issn-type":[{"value":"2731-9229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used Gemini and ChatGPT for grammar and English language editing. After using these tools, the authors reviewed and edited the content as needed and take full responsibility for the content of the manuscript.","order":4,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"365"}}